Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
Off-label use of dalbavancin to improve treatment outcomes and reduce health care costs in people who use drugs: A Canadian single-centre quality improvement initiative.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gunton Adrianna N, Pavan Mara, Leung Victor, Murray Melanie Cm, Connors William J
Аннотация
BACKGROUND: Dalbavancin is approved in Canada for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). We present a single-centre quality improvement case series of dalbavancin use in serious bacterial infections in people who use drugs (PWUD). Our goal was to facilitate access to dalbavancin to improve treatment outcomes and identify potential health system savings.
METHODS: We established an unrestricted, hospital-specific, rapid-access compassionate provision program for dalbavancin. Patients were considered for treatment with dalbavancin at the discretion of an infectious diseases physician if they had serious gram-positive infections. Patients provided informed verbal consent. Data were collected via retrospective chart review. We compared costs savings using a practitioner modifiable cost calculator developed by Paladin Labs Inc.
RESULTS: Between September 2022 and November 2023, seven patients received dalbavancin. The most common indications for use included early discharge from hospital and improved treatment adherence. Three patients were considered to have infection cure at last follow-up, three patients were presumed to have infection cure but were lost to follow-up, and one patient had infection relapse. Two patients died from causes unrelated to the dalbavancin-treated condition. There were no reported adverse events. Dalbavancin resulted in cost savings compared with standard-of-care (SoC) treatment, and this was primarily driven by reduced inpatient hospital days.
CONCLUSIONS: Dalbavancin may improve treatment adherence and outcomes for PWUD with serious gram-positive infections while saving health care costs by facilitating earlier discharge from hospital. Our preliminary experience highlights the need for additional controlled studies to evaluate expanded indications for dalbavancin as well as innovative approaches to increase access to novel antimicrobial agents in a single-payer health care system such as Canada.
METHODS: We established an unrestricted, hospital-specific, rapid-access compassionate provision program for dalbavancin. Patients were considered for treatment with dalbavancin at the discretion of an infectious diseases physician if they had serious gram-positive infections. Patients provided informed verbal consent. Data were collected via retrospective chart review. We compared costs savings using a practitioner modifiable cost calculator developed by Paladin Labs Inc.
RESULTS: Between September 2022 and November 2023, seven patients received dalbavancin. The most common indications for use included early discharge from hospital and improved treatment adherence. Three patients were considered to have infection cure at last follow-up, three patients were presumed to have infection cure but were lost to follow-up, and one patient had infection relapse. Two patients died from causes unrelated to the dalbavancin-treated condition. There were no reported adverse events. Dalbavancin resulted in cost savings compared with standard-of-care (SoC) treatment, and this was primarily driven by reduced inpatient hospital days.
CONCLUSIONS: Dalbavancin may improve treatment adherence and outcomes for PWUD with serious gram-positive infections while saving health care costs by facilitating earlier discharge from hospital. Our preliminary experience highlights the need for additional controlled studies to evaluate expanded indications for dalbavancin as well as innovative approaches to increase access to novel antimicrobial agents in a single-payer health care system such as Canada.